Skip to main content

Evofem Biosciences, Inc.

For the period ended Mar 31, 2026. Filed May 15, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 15, 2026

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

What changed in Risk Factors?

Read the current filing

The baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.

Compared 12 previous paragraphs and 10 current paragraphs.

8 unchanged; 1 reworded; 1 added; 3 removed; 0 previous and 0 current paragraphs rearranged.

Tables are not compared: 3 previous and 3 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.

A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.

Added paragraphs (1)

Current report

As of the filing date, the Company does not have any defaults on any Senior Securities which have not already been disclosed in a Form 8-K.
Removed paragraphs (3)

Previous report

Item 6. Exhibits

Previous report

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index.
Reworded paragraphs (1)

Previous wording

There have not been any material changes to the risk factors disclosed in our Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 24, 2025 and amended on March 28, 2025.

Current wording

There have not been any material changes to the risk factors disclosed in our Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 11, 2026.